Hesperco
-
Steve Saviuk on Valeo Pharma’s TSX Listing and Q1-22 revenues of $4.2 million, up 128% over Q1-21
In a recent InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Valeo Pharma launches Redesca™ and is forecasting company revenues to increase 20x by 2025
Bringing new pharmaceutical products to market is a long and expensive process. One Canadian company has found an…
-
Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio
COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a…
-
Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19
In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…
-
Valeo Pharma’s approval and launch of immune support product line Redesca and Redesca HP anticipated to impact first half 2021 revenue
Most investors know that the pharmaceutical industry is a huge and mostly very profitable industry. What they may…
